SPLUNC1 protein in host defense against Mycoplasma pneumoniae infection
SPLUNC1 protein in host defense against Mycoplasma pneumoniae infection
批准号:
7839374
负责人:
Hong W Chu
金额:
$25.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30
关键词:
AcuteAllergicAnti-Inflammatory AgentsAnti-inflammatoryAntibioticsAsthmaAttenuatedBacteriaBacterial InfectionsBindingCell Culture TechniquesChronicChronic Obstructive Airway DiseaseDataDependenceDiseaseEpithelialEpithelial CellsFamilyGrowthHost DefenseHumanIL8 geneIn VitroInfectionInflammationInflammatoryInflammatory ResponseInterleukin-13InvadedInvestigationKnowledgeLeadLengthLigandsLipoproteinsLungLung diseasesMethodsMolecularMusMutateMycoplasma pneumonia infectionMycoplasma pneumoniaeNF-kappa BNasal EpitheliumNuclearPalatePathway interactionsPredispositionProcessProductionProtein BindingProteinsRNA InterferenceReceptor CellRegulationResearchRoleSTAT6 geneSignal TransductionTLR1 geneTLR6 geneTestingTimeToll-Like Receptor 2Transgenic MiceUp-Regulationairway epitheliumairway inflammationantimicrobialcytokinedesigneffective therapyheat-shock factor 1human large airway epithelial cellin vivomouse modelnovelnovel therapeuticspathogenpreventpublic health relevancerespiratorytranscription factor
中文摘要
描述(由申请人提供):哮喘患者患有气道中的急性或慢性感染(例如,肺炎支原体[Mp],一种非典型细菌)。迄今为止,哮喘患者易受细菌感染的机制在很大程度上是未知的。气道上皮细胞在宿主防御病原体入侵中起着至关重要的作用。腭、肺、鼻上皮克隆蛋白(PLUNC)是一类新的宿主防御分子。短型PLUNC1 (SPLUNC1)在人和小鼠大气道上皮中大量表达。本课组的初步研究表明:(1)SPLUNC1蛋白在人和小鼠正常而非过敏的大气道上皮细胞中大量存在;(2)人和小鼠SPLUNC1蛋白在toll样受体2 (TLR2)配体刺激下抑制Mp生长和上皮IL-8的产生;(3) Mp感染增加上皮SPLUNC1,变应性炎症或Th2细胞因子IL-13降低SPLUNC1;(4) SPLUNC1诱导依赖于TLR2信号的激活。这些研究得出以下中心假设:SPLUNC1蛋白在宿主防御呼吸道细菌(如Mp)感染中起关键作用。在Th2细胞因子环境的存在下,感染时气道上皮SPLUNC1产生的预期增加被抑制,导致持续的气道细菌感染和炎症。为了验证这一假设,我们提出了三个目标。目的1是测试SPLUNC1蛋白是否通过以下途径发挥宿主防御和抗炎功能:a)直接抑制细菌生长;B)与细菌成分(如脂蛋白)结合;c)与宿主细胞受体(即TLR2)结合并随后抑制细菌或细菌成分的信号传导。我们将生成野生型和突变的SPLUNC1蛋白和可溶性TLR2来验证这一特定假设。目的2是验证Mp单独增加TLR2信号活性,导致上皮SPLUNC1上调的特定假设。Th2细胞因子环境(如IL-13)抑制Mp诱导的TLR2信号激活和随后的SPLUNC1产生,从而损害Mp清除。转录因子核因子κ B (NF-?B)和热休克因子-1 (HSF-1)在TLR2刺激后被激活,并直接增强SPLUNC1的表达。将进行原代气道上皮细胞培养,使用分子方法(例如RNA干扰)在Th2细胞因子环境中结合Mp感染、TLR2信号和SPLUNC1调控。目的3是使用小鼠模型来支持我们在目的1和2中的体外数据:1)SPLUNC1对肺防御Mp至关重要;2) IL-13降低TLR2信号,从而损害肺SPLUNC1和Mp的清除。Tlr2 hsf-1 nf -?我们将利用TLR2信号在Th2细胞因子环境下调控SPLUNC1表达和功能的作用。我们提出的研究将揭示哮喘患者对感染易感性增加的新分子机制,这将导致发现减轻气道感染的有效治疗方法。公共卫生相关性。尽管使用了各种市售抗生素,但气道细菌感染继续对包括哮喘在内的肺部疾病构成重大挑战。哮喘是一种常见病,困扰着美国和世界各地的人们。我们的研究结果将大大提高我们对哮喘患者对肺部细菌感染易感性增加的分子机制的理解,从而有助于设计新的治疗策略,以减轻哮喘和其他慢性肺部疾病的气道感染和炎症过程。
英文摘要
DESCRIPTION (provided by applicant): Asthmatics are afflicted with acute or chronic infections (e.g., Mycoplasma pneumoniae [Mp], an atypical bacterium) in the airways. To date, the mechanisms by which asthmatics are susceptible to bacterial infections are largely unknown. Airway epithelial cells are critical in host defense against the invading pathogens. Palate, lung, and nasal epithelium clone (PLUNC) proteins are a new family of host defense molecules. Short PLUNC1 (SPLUNC1) is abundantly expressed in large airway epithelium of humans and mice. Preliminary studies from our group demonstrated that: (1) SPLUNC1 protein exists in large quantities in normal, but not allergic, large airway epithelial cells of humans and mice; (2) Human and mouse SPLUNC1 proteins inhibit Mp growth and epithelial IL-8 production upon stimulation with Toll-like receptor 2 (TLR2) ligands; (3) While Mp infection increases epithelial SPLUNC1, allergic inflammation or the Th2 cytokine IL-13 decreases SPLUNC1; and (4) SPLUNC1 induction is dependent on TLR2 signaling activation. These studies led to the following central hypothesis: SPLUNC1 protein is critical in host defense against respiratory bacterial (e.g., Mp) infections. In the presence of a Th2 cytokine milieu, the expected increases of airway epithelial SPLUNC1 production upon an infection are dampened, leading to a persistent airway bacterial infection and inflammation. To test this hypothesis, we propose three aims. Aim 1 is to test whether SPLUNC1 protein exerts host defense and anti-inflammatory functions through: a) direct inhibition of bacterial growth; b) binding to bacterial components (e.g., lipoproteins); and c) binding to host cell receptors (i.e., TLR2) and subsequently inhibiting the signaling of bacteria or bacterial components. We will generate wild-type and mutated SPLUNC1 proteins and soluble TLR2 to test this specific hypothesis. Aim 2 is to test the specific hypothesis that Mp alone increases TLR2 signaling activity, leading to epithelial SPLUNC1 up-regulation. A Th2 cytokine milieu (e.g., IL-13) inhibits Mp-induced TLR2 signaling activation and subsequent SPLUNC1 production, thereby impairing Mp clearance. Transcription factors nuclear factor kappa B (NF-?B) and heat shock factor-1 (HSF-1) are activated upon TLR2 stimulation, and directly enhance SPLUNC1 expression. Primary airway epithelial cell cultures will be performed to tie Mp infection, TLR2 signaling and SPLUNC1 regulation in a Th2 cytokine milieu using molecular methods (e.g., RNA interference). Aim 3 is to use mouse models to support our in vitro data from Aims 1 and 2 in that: 1) SPLUNC1 is critical to lung defense against Mp; 2) IL-13 decreases TLR2 signaling, thus impairing lung SPLUNC1 and Mp clearance. TLR2, HSF-1, NF-?B pathway and STAT6 deficient, and IL-13 transgenic mice will be used to prove the role of TLR2 signaling in regulating SPLUNC1 expression and functions under a Th2 cytokine milieu. Our proposed studies will reveal novel molecular mechanisms responsible for an increased susceptibility of asthmatics to infections, which will lead to the discovery of effective therapy in attenuating airway infections. PUBLIC HEALTH RELEVANCE. Despite the use of various commercially available antibiotics, airway bacterial infections continue to pose a significant challenge in lung diseases including asthma. Asthma is a common disease that afflicts people in the US and worldwide. Our research findings will significantly advance our knowledge in understanding the molecular mechanisms responsible for an increased susceptibility of asthmatics to bacterial infections in the lung, thus helping the design of novel therapeutic strategies in attenuating airway infectious and inflammatory processes in asthma and perhaps in other chronic pulmonary diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of immunoproteasome in airway viral infection
-
批准号:10155416
-
项目类别:
-
资助金额:$56.32万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
-
批准号:10264924
-
项目类别:
-
资助金额:$73.14万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Role of immunoproteasome in airway viral infection
-
批准号:10398121
-
项目类别:
-
资助金额:$55.59万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
-
批准号:10457989
-
项目类别:
-
资助金额:$72.92万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Role of immunoproteasome in airway viral infection
-
批准号:10610373
-
项目类别:
-
资助金额:$55.59万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Parkin in mitochondrial dysfunction and airway inflammation of obese asthma
-
批准号:10675493
-
项目类别:
-
资助金额:$71.84万
-
财政年份:2020
-
负责人:Hong W Chu
-
依托单位:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
-
批准号:10005959
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2018
-
负责人:Hong W Chu
-
依托单位:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
-
批准号:10241973
-
项目类别:
-
资助金额:$46.59万
-
财政年份:2018
-
负责人:Hong W Chu
-
依托单位:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
-
批准号:9626290
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2018
-
负责人:Hong W Chu
-
依托单位:
Immunosuppressive injurious effects of e-cigarettes on human lung parenchyma
-
批准号:9789355
-
项目类别:
-
资助金额:$48.36万
-
财政年份:2018
-
负责人:Hong W Chu
-
依托单位:
Tollip inhibits IL-33 signaling during airway influenza virus infection
-
批准号:10661667
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2016
-
负责人:Hong W Chu
-
依托单位:
Tollip inhibits IL-33 signaling during airway influenza virus infection
-
批准号:10473859
-
项目类别:
-
资助金额:$28.44万
-
财政年份:2016
-
负责人:Hong W Chu
-
依托单位:
Tollip inhibits IL-33 signaling during airway influenza virus infection
-
批准号:10261956
-
项目类别:
-
资助金额:$33.26万
-
财政年份:2016
-
负责人:Hong W Chu
-
依托单位:
SPLUNC1 in Severe Asthma
-
批准号:8851736
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2015
-
负责人:Hong W Chu
-
依托单位:
SPLUNC1 in Severe Asthma
-
批准号:9174103
-
项目类别:
-
资助金额:$4.44万
-
财政年份:2015
-
负责人:Hong W Chu
-
依托单位:
Novel function of MUC18: amplification of inflammation in allergic lungs
-
批准号:8817206
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2014
-
负责人:Hong W Chu
-
依托单位:
Novel function of MUC18: amplification of inflammation in allergic lungs
-
批准号:9189643
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2014
-
负责人:Hong W Chu
-
依托单位:
IRAK-M in lung defense against rhinovirus infection
-
批准号:9184525
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2013
-
负责人:Hong W Chu
-
依托单位:
IRAK-M in lung defense against rhinovirus infection
-
批准号:8986151
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2013
-
负责人:Hong W Chu
-
依托单位:
IRAK-M in lung defense against rhinovirus infection
-
批准号:8630524
-
项目类别:
-
资助金额:$41.9万
-
财政年份:2013
-
负责人:Hong W Chu
-
依托单位:
海外基金